Skip to main content
. Author manuscript; available in PMC: 2023 Feb 19.
Published in final edited form as: Science. 2022 Aug 19;377(6608):eabk0637. doi: 10.1126/science.abk0637

Fig. 6. Biofluid GPNMB protein levels associate with rs199347 genotype, PD diagnosis, and disease severity.

Fig. 6.

(A) Plasma and (B) CSF GPNMB levels grouped by rs199347 genotype. Genotypes compared with Kruskal-Wallis test, followed by post-hoc Dunn’s test. ** p < 0.01. (C) Plasma and (D) CSF GPNMB levels grouped by diagnosis. PD (red) vs. neurologically normal controls (NC, blue) compared by Mann-Whitney test. Boxplots depict median, 25th, 75th quartiles, while whiskers are full range. ** p < 0.01. (E) Demographics for discovery and replication cohorts used for UPDRS-PIII analysis. (F-G) Scatterplots showing positive correlation between UPDRS-PIII scores and plasma GPNMB values in discovery (F) and replication (G) cohorts. Spearman’s rho and p-value displayed in text.